Pre-Exposure Prophylaxis for HIV Upfront
Pre-Exposure Prophylaxis for HIV Upfront
Carmen de Mendoza
Puerta de Hierro University Hospital, Madrid, Spain
*Correspondence: Carmen de Mendoza, Email not available
Abstract
The recent publication of two trials, CAPRISA (Abdoool-Karim, et al. Science. 2010;329:1168-74) and iPrEX (Grant, et al. N Engl J Med. 2010;363:2587-99) last year has raised in an unprecedented manner the interest for pre-exposure prophylaxis (PrEP) as a way to confront the HIV pandemic. CAPRISA examined nearly 900 heterosexually active women in South Africa and demonstrated that use of the topical vaginal tenofovir reduced the risk of HIV acquisition by 39% overall, rising to 54% in those women with high gel adherence.
